Mount Sinai Researchers Identify Mechanisms and Potential Biomarkers of Tumor Cell Dormancy
May be able to recreate conditions that keep cancer cells from growing after they have spread.
Oncologists have long puzzled over the fact that after cancer treatment, single cancer cells that are dispersed throughout the body – so-called disseminated tumor cells – are quick to grow and form secondary tumors called metastases in certain organs, while in other organs they metastasize more slowly, sometimes decades later. Such is the case with head and neck squamous cell carcinoma (HNSCC) cells, which remain dormant when lodged in bone marrow but rapidly form tumors when they make their way into the lungs.
A study published online October 27 by Nature Cell Biology by Bragado et al. reveals that bone marrow contains high levels of TGFβ2, which activates the tumor suppressor gene p38 in tumor cells and triggers a cascade of events that renders tumor cells dormant and keeps HNSCC growth in check. In the lungs, where TGFβ2 is in short supply, these cells rapidly form tumors.
The research team, led by Julio A. Aguirre-Ghiso, PhD, Associate Professor of Medicine, Hematology and Medical Oncology, and Otolaryngology at the Icahn School of Medicine at Mount Sinai, is the first to identify the role of TGFβ2 in determining whether HNSCC cells will remain harmlessly dormant or behave aggressively in a given location. The study confirms a century-old theory called the "seed and soil" theory of metastasis, which suggests that a tumor cell – the seed – either sleeps or thrives within the unique environment of each organ – the soil.
"Our study provides critical evidence to explain why tumor cells gain a firm foothold in certain organs but not in others, where they can remain inactive for long periods of time," explained Dr. Aguirre-Ghiso.
Approximately 80 percent of the animal models the researchers studied contained disseminated HNSCC cells in the lungs, while less than 30 percent contained tumor cells in the bone marrow. After removing the primary tumors, the number of disseminated tumor cells in the bone marrow remained the same for several weeks (equivalent to ~ 3 years in humans). However, the number of tumor cells in the lungs increased shortly after the tumors were removed, suggesting that conditions within each organ had a long-lasting effect on the cells’ behavior.
In addition, the researchers discovered that lowering TGFβ2 or p38 levels awakened dormant cells and fueled metastatic growth throughout the body.
These findings may have implications for estrogen-positive breast tumor cells, which have a similar genetic signature to that of dormant HNSCC cells.
"Our study is the first to identify specific characteristics found in cancer cells as well as in the microenvironment in which they are found that determine whether they will metastasize rapidly, posing a new threat to the patient, or will remain dormant for a period of time," said Dr. Aguirre-Ghiso. "Eventually, we may be able to predict, based on markers detected in disseminated tumor cells and/or in the microenvironment, which patients have a dormant disease and which ones will need more aggressive treatment. This information may also lead to the development of new drugs that mimic the pathways that prevent tumor cells from metastasizing."
About the Mount Sinai Health System
Mount Sinai Health System is one of the nation’s leading integrated academic health systems and one of the largest in the New York metropolitan area. Its comprehensive system includes seven hospitals, more than 400 outpatient practices, over 600 research and clinical laboratories, the Icahn School of Medicine at Mount Sinai, the Graduate School of Biomedical Sciences, and the Mount Sinai Phillips School of Nursing. Together, the Health System comprises approximately 48,000 employees, more than 9,000 physicians, and 8,600 nurses.
As a leading learning health system, Mount Sinai combines clinical expertise with scientific discovery to improve patient care while training the next generation of health care and biomedical leaders. The Health System provides care across every stage of life, from prenatal care through geriatrics, while advancing personalized medicine through artificial intelligence, data science, and biomedical research.
Mount Sinai is consistently recognized among the nation’s leading academic health systems for patient care, research, and education. The Mount Sinai Hospital is ranked No. 1 in New York by Newsweek and No. 5 on the magazine’s World’s Best Hospitals list. The Icahn School of Medicine at Mount Sinai ranks No. 11 among U.S. medical schools and No. 1 among freestanding medical schools for National Institutes of Health funding, reflecting the strength of its scientific enterprise and leadership in biomedical research.
Researchers Identify Immune Cell That Builds Cancer-Fighting Hubs Inside Tumors
Jul 16, 2026 View All Press Releases
Loss of Radiation Therapy Clinics Could Widen Cancer Care Gaps Across the United States
Jul 10, 2026 View All Press Releases
Cancer-Associated Mutations in Brain Immune Cells May Contribute to Alzheimer's Disease
Jun 11, 2026 View All Press Releases
Reversing T Cell Exhaustion Improves Effectiveness of Myeloma Immunotherapies
May 18, 2026 View All Press Releases